What is the Value of an FDA Approval in a Judicial Matter? by Friedman, Michael A.
Journal of Law and Policy
Volume 12
Issue 2
SCIENCE FOR JUDGES II:
The Practice of Epidemiology and Administrative
Agency Created Science
Article 6
2004
What is the Value of an FDA Approval in a Judicial
Matter?
Michael A. Friedman
Follow this and additional works at: https://brooklynworks.brooklaw.edu/jlp
This Article is brought to you for free and open access by the Law Journals at BrooklynWorks. It has been accepted for inclusion in Journal of Law and
Policy by an authorized editor of BrooklynWorks.
Recommended Citation
Michael A. Friedman, What is the Value of an FDA Approval in a Judicial Matter?, 12 J. L. & Pol'y (2004).
Available at: https://brooklynworks.brooklaw.edu/jlp/vol12/iss2/6
FRIEDMANMACRO.DOC 4/23/2004 12:53 PM 
 
559 
WHAT IS THE VALUE OF AN FDA 
APPROVAL IN A JUDICIAL MATTER? 
Michael A. Friedman, M.D.* 
INTRODUCTION 
The central role of the Food and Drug Administration (FDA) in 
our daily lives is so great that no single, brief paper permits a deep 
or nuanced discussion of any of its many components, much less 
the legal framework of FDA drug provisions. Consequently, this 
paper provides a condensed view of a few topics that, from a 
judicial perspective, might be the issues of greatest interest to a 
presiding judge. 
The range of FDA responsibilities is vast and complex, and 
includes food, medical devices, veterinary products, blood, 
vaccines, cosmetics, and over the counter remedies.1 Here, I will 
focus only on pharmaceutical products. In the interests of full 
disclosure, my views are entirely personal (certainly not FDA’s) 
and informed by my own experience. I have participated, one way 
or another, in almost every aspect of the health care system that 
might affect a judicial consideration. I have practiced medicine and 
taught at an academic medical school. I have worked for the 
federal government, both at the National Institutes of Health and at 
the Food and Drug Administration (where I served as Acting 
Commissioner). I have worked for a pharmaceutical manufacturer, 
and now I am back in academia as President and CEO of the City 
of Hope. This aggregate experience means, I hope, that my 
                                                          
 * Michael A. Friedman, M.D. is President and CEO of City of Hope, a 
federally designated comprehensive cancer center in Duarte, California. 
1 See Dep’t of Health & Human Serv., U.S. Food & Drug Admin., Products 
FDA Regulates, at http://www.fda.gov/default.htm (last visited Mar. 7, 2004). 
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remarks will neither be perceived as too defensive of any one of 
these institutions, or totally uninformed. But, there is always the 
danger of a subtle, unintended bias. 
Were I sitting on the bench and judging a case involving a drug 
product, there are two questions I might consider with reference to 
the FDA approval process. They would be: (1) is the regulatory 
process a rigorous one and, (2) are the regulatory findings accurate. 
These two concerns necessarily go hand in hand in determining the 
evidentiary value of an FDA drug approval. 
This paper consists of three parts: first, a very brief description 
of the general process of pharmaceutical product development 
(R&D), which provides relevant background about how research 
information is generated by a pharmaceutical manufacturer and 
presented to the FDA for review; second, an equally brief 
description of the FDA review process; and third, an examination 
of some of the characteristics and limitations of this review FDA 
process. 
I. PHARMACEUTICAL R&D 
A. The Process 
The complex difficulties of developing a new drug product are 
truly formidable. Figure 1 is a schematic that generally represents a 
process that often takes more than 15 years.2 A substantial 
component, perhaps one third, of this expensive and complex 
process is the screening of molecules, in vitro testing, and animal 
studies to try and identify a suitable biological target and find 
molecules that affect that target in some clinically useful way. 
 
 
                                                          
2 See FDA CTR. FOR DRUG EVALUATION & RESEARCH, FROM TEST TUBE 
TO PATIENT: IMPROVING HEALTH THROUGH HUMAN DRUGS (3d ed. 1999), 
available at http://www.fda.gov/cder/about/whatwedo/testtube-full.pdf; see also 
Richard J. Findlay, Originator Drug Development, 54 FOOD DRUG L.J. 227, 
227-28 (1999) (stating that the development process for a new drug takes an 
average of 14.7 years). 
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FIGURE 1—TYPICAL DRUG DEVELOPMENT TIME 
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Next, clinical testing in humans can begin. First, initial toxicity 
and pharmacology studies (Phase I) are conducted, followed by 
preliminary efficacy trials (Phase II), and then, large randomized 
studies are used to definitely identify the benefits and get more 
precise information about the toxicities of that particular medicine 
(Phase III). 
There are interactions between the industrial sponsor and FDA 
throughout this entire sequence. At the end of this process, there is 
FDA review and, if appropriate, approval for commercial 
marketing. Thereafter, for almost every product there continues to 
be additional post-marketing studies. The post-marketing studies 
(Phase IV) are among the most important of all, because even after 
a 15-year, $900 million effort, at the time of FDA approval there is 
relatively limited prescribing information available. Simply put, 
we learn progressively much more information about a product 
over time. 
As an investor, from a purely financial point of view, it would 
probably be more prudent to invest in oil prospecting than in 
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pharmaceutical development. With modern geology techniques, 
wildcatting for oil wells is statistically more successful than 
finding a new drug that goes to market. Perhaps only one in 5,000 
screened candidate molecules even begins development. Only one 
fifth of those actually complete clinical trials. Only one third of 
those are finally completely approved by FDA. So, overall, the 
odds of success for a new drug are not at all favorable.3 This 
represents, if you will, a winnowing process through which all 
products need to pass. 
The costs of completing all these steps are enormous. In 1976, 
the average cost of developing a new drug was about $167 million. 
Today, it is in excess of $900 million.4 This figure does not mean 
drug development is necessarily being well done nor that the data 
derived from R&D studies are necessarily more valid, useful, or 
appropriate. This is simply the conventional cost of performing this 
kind of research to bring a product to market, and there are many 
reasons why drug discovery and development are so very difficult. 
B. Why Is Drug Discovery So Difficult? 
The basic hurdle is that new drugs are, by their nature, new. 
The targets are new; the toxicities will be new; the nuances of how 
to use the product will be new. 
Second, no matter how carefully we screen compounds in 
animal model systems, the differences between mammalian species 
are dramatic, vast, and incompletely understood. So, although we 
may derive a lot of useful information from mouse, rat, and dog 
studies, we do not have all the relevant information necessary for 
human use. 
Third, people vary and so do diseases. Even when we focus on 
a particular disease category (like diabetes or cancer) we realize 
                                                          
3 Henry Grabowski, Pharmaceuticals: Politics, Policy and Availability: 
Patents and New Product Development in the Pharmaceutical and 
Biotechnology Industries, 8 GEO. PUB. POL’Y REV. 7, 8-10 (2003). 
4 See FDA CTR. FOR DRUG EVALUATION & RESEARCH, supra note 2, at 15 
(stating that a company like Hoffman-La Roche spends about $1 billion in 
research worldwide). Parenthetically, while some in the pharmaceutical industry 
are proud of this fact ($900 million cost), I think it is appalling. 
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that there are many subtypes and forms. Moreover, nature tends to 
be rather conservative. Just when you think you have found a way 
of exploiting a biologic opportunity, you find that it is too toxic or 
not medically successful. Another way of saying this is, you do not 
get something for nothing in pharmaceuticals (or in medical 
interventions of any sort). Science, notwithstanding what scientists 
sometimes proclaim, is incremental and incomplete. For every 
biologic question that is answered, a dozen more are raised that are 
more vexing and more formidable. There certainly are no 
shortcuts. 
Furthermore, there are some very fine pharmaceutical 
companies and very competent scientists who spend their entire 
careers trying to develop better drugs. Yet, I think it is safe to say 
that in this endeavor no one is truly an expert; no one has a full 
understanding of the development process. It is getting more and 
more difficult to develop new drugs and the business and scientific 
decisions are very tough and the risks are very high. 
II. FDA REVIEW 
FDA review begins prior to the first human administration, 
and, in a sense, never ceases. Even after a drug is approved for 
sale, information is still gathered on that drug, albeit less 
intensively, less formally, and less regularly. Nonetheless, it is still 
gathered. Although the approval of a new product is a sort of 
watershed, it is not the final point in understanding how to 
optimally use that medication or what its side effects may be. 
There are formal meetings that take place between FDA, the 
drug sponsor, and the pharmaceutical company, all at specified 
time points, usually before the initiation of major clinical trials. 
Additionally, there are informal meetings that may occur any 
time—telephone meetings, face-to-face meetings, and exchange of 
written materials and so forth. 
All of the animal data, the toxicology, and the pharmacology 
data are reviewed, and then all of the clinical data are reviewed. In 
fact, there is a scrutiny of the primary data. What does this mean? 
There are often several thousand patients in the clinical dossier that 
a company presents to the FDA. And, in fact, over the past two 
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decades the size of that dossier has grown. Today, it is typical to 
have 1,000 to 5,000 subjects. For some products as many as 
40,000-50,000 patients/subjects may be studied. While 50,000 may 
seem like a large number, it is actually only minimally satisfactory. 
All the primary clinical information about the subjects—
pathology reports, x-rays, blood reports, etc.—is made available 
for FDA review. Typically, FDA does not review every single case 
record individually. In a study where there may be dramatic 
benefit, however it would not be unusual to have FDA review 
those materials that document the purported efficacy (and to do so 
in some considerable detail). There are also on-site inspections. If 
there are 100 hospitals that participate in a clinical trial, FDA may 
visit some of those hospitals, go to the radiology department to 
look at pertinent x-rays, or go to the medical record room to review 
patient files to make sure that the data reported in summary form is 
actually supported by the primary documentation.5 
Formally noted review interactions occur when FDA meets 
with the sponsor. These are summarized and memorialized. When 
the entire body of information is finally prepared for a definitive 
regulatory decision, there is often (but not always) a public 
advisory committee meeting. A group of scientists and lay 
representatives who do not have any overt conflicts of interest 
analyze the dossier materials at a public hearing. The 
pharmaceutical manufacturer makes a presentation, the agency 
makes a presentation, there is time for comments from the 
audience (from patient advocacy groups or individuals), and there 
is an open discussion of the value and the toxicity of that product. 
The United States FDA also communicates with sister foreign 
regulatory bodies, such as the European Union Food and Drug 
Administration and the Health Protection Agency of Canada, to 
distribute information shared and perspectives. 
                                                          
5 See U.S. Food & Drug Admin., Ctr. for Drug Evaluation & Research, at 
http://www.fda.gov/cder/about/smallbiz/humans.htm (last visited Mar. 7, 2004) 
(describing Institutional Review Board’s procedures on-site inspections and data 
audits designed to monitor all aspects of the conduct and reporting of FDA 
regulated research). 
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III. FEATURES OF FDA REVIEW 
What are the characteristics of FDA review? Briefly, the 
overall review process is a good and thoughtful one with a number 
of strengths and advantages. First, there is no consistent or 
systematic bias. This is a scientifically sophisticated, objective 
review of information. The potential for conflicts of interests are 
minimized. Every agency official or reviewer has personal, social, 
economic, intellectual, philosophic, and even political 
perspectives. These are certainly recognized, but their impact is 
minimized within the agency. FDA staff overtly act in a way to 
give the best, dispassionate review of information. Moreover, there 
are multiple layers of expert review so that a junior reviewer has 
her review scrutinized at the next administrative level and so forth. 
Some very important product decisions are elevated, even to the 
level of the commissioner, to assure that there is a critical re-
evaluation of all of the judgments and processes that have gone 
into formulating that decision. To its advantage, this process is 
moderately transparent. Except for patented intellectual property 
and certain commercial confidential information, everything else is 
disclosed to the public.6 
So, the clinical information, the patient summaries that are 
used to determine survival or toxicity or efficacy information, are 
made available to the public for their scrutiny and evaluation. It 
should be recognized that although the statutory basis for review 
(the Food, Drug & Cosmetic Act, for example), directs that a 
product be “safe and effective” in order to receive FDA approval, 
this is really a relative standard, not an absolute one.7 As everyone 
appreciates, nothing, and certainly no medication, is entirely 
“safe.” It is well documented that an 81mg “baby” aspirin can 
rarely cause a fatal stroke or a massive stomach hemorrhage. A 
                                                          
6 See U.S. Food & Drug Admin., Ctr. for Drug Evaluation & Research, 
Institutional Review Boards and Protection of Human Subjects in Clinical 
Trials, at http://www.fda.gov/cder/ (last visited Mar. 7, 2004). 
7 21 C.F.R.§ 314.105 (c) (1999); Jill Wechsler, Risk Management Shapes 
FDA Policies and Practices; Washington Report; Controls to Ensure Safety of 
New Drugs, PHARMACEUTICAL TECH. Aug. 1, 2002, at 12 (stating that no drug is 
100% safe). 
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product that is given to millions of people every day can (in rare 
instances), unfortunately, be lethal to a particular individual. 
Similarly, nothing is universally efficacious. No matter how good a 
product is, no matter how “effective” it may be for the majority of 
patients, no product helps every single patient. And so we have to 
recognize that the legal standards here are not ideal—rather, in the 
real world, they are relative. 
While FDA’s most comprehensive and most critical reviews 
are the careful assessments made at the time of initial product 
approval, this may not be the only important review. There is 
routine monitoring of accumulated data after a product is made 
commercially available.8 But this capture of post-marketing 
information tends to be relatively inconsistent. Consequently, only 
infrequently does formal FDA re-review have the same 
characteristics as the primary review and approval. The initial 
review is a powerful means for detecting large biologic signals. 
Dramatic benefit or unusual or frequent side effects can be easily 
recognized. However, this initial review is less effective for 
detecting subtle (but important) signals. This should not be 
construed as a criticism of the FDA reviewers or the process as it 
exists. It is just that for very subtle toxicity, or side effects that are 
inconsistently or unpredictably observed, or toxicities commonly 
attributed to other factors, the initial review may have limited 
utility. 
One source of confusion is with the evaluation of common or 
mild toxicities. A brand new product may cause headache. But, 
headache is a rather common complaint (one that people 
experience all the time). It is difficult to distinguish between a 
headache that is a side effect of a drug and a headache that we all 
suffer (for any number of reasons). The ability to detect rare, but 
critically meaningful adverse events may not be simple; thus there 
are clear limitations of the regulatory approval process. For 
example, the number of patients included a typical dossier that is 
submitted by a drug company for FDA review today will almost 
certainly grow in size over the next decade. With a clinical sample 
                                                          
8 Lara Noah, Informed Consent and the Elusive Dichotomy between 
Standard and Experimental Therapy, 28 AM. J.L. & MED. 361, 394-400 (2002). 
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denominator of 10,000, you can reliably detect an important, novel 
toxicity (one typically identified in the average package insert) at 
about the 1% level. However, you might need 750,000 subjects to 
even be able to accurately perceive a rare (but lethally important) 
toxicity and recognize that it is a real signal (and not just 
confounding background noise). 
In practice, drug recalls and civil actions are based upon 
critical side effects occurring in only 1 in 250,000 to 1 in 500,000. 
So, a drug like Duract, a non-steroidal anti-inflammatory drug that 
caused fatal liver toxicity extremely rarely, was not clearly 
perceived to be a risk until some 2.5 million people had taken it.9 
While the number of people who suffered serious liver toxicity was 
extremely small, the drug was removed from the market because it 
is unacceptable to have even this tiny chance of liver toxicity when 
there are inexpensive, safer, and easily available alternatives (such 
as ibuprofen). 
In order to reliably detect a rare but important toxicity, 
however, you may need many millions of individuals exposed, 
although it is inconceivable that you will have millions of 
individuals evaluated as part of the primary review. Were that the 
case, almost no new drug would ever be approved. So, no matter 
how good the initial screen is, it will only be later, when the drug is 
in widespread distribution and broad use, that you are able to 
detect some of the most critical and important side effects. 
If, as I maintain, that FDA review is rigorous but imperfect, 
there are several sources of “error” that need consideration. By 
“error,” I mean conclusions, which at a point in time appear to be 
valid, but which actually are not (that is, they are different from 
reality). The most infamous, but actually the rarest cause of error, 
is outright fabricationthe determination that the submitted 
dossier is purposefully false. For example, this might happen if the 
investigator did not do the experiment or faked patient data. Such 
occurrences are very dramatic and they are usually well 
publicized.10 By every measure they seem to be exceedingly 
                                                          
9 Barbara A. Noah & David B. Brushwood, Adverse Drug Reactions in 
Elderly Patients: Alternative Approaches to Postmarket Surveillance, 33 J. 
HEALTH L. 383, n. 7 (2000). 
10 See FDA CTR. FOR DRUG EVALUATION & RESEARCH, supra note 2, at 
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uncommon, but they certainly do occur. 
Such falsifications are detected by scientific replication. For 
instance, if a manufacturer fraudulently claims that it “has a 
treatment that cures AIDS patients,” that medicine is thus 
approved, and then lots of other physicians prescribe that marketed 
medication and it does not cure AIDS patients, scientific journals 
will begin to publish studies that say the medicine does not in fact 
work. The product will be recalled or reexamined because 
scientific replication will eventually show that there has been a 
major lie. 
More commonly, but still relatively uncommon, is sloppiness. 
The distinction between purposeful and accidental error from a 
patient point of view is null. By this I mean that although the one is 
evil and the other is just clumsy, they are both utterly 
unacceptable. Misinformation, no matter how innocently 
generated, still does harm. But how do you guard against 
sloppiness? It is by that elaborate system of reviewing primary 
patient records, comparing data tapes and files to the original 
materials, and making sure that data entries are accurately 
transcribedissues as simple as making sure that you do not mix 
up records from Patient A with Patient B, or Study 1 with Study 2. 
One difference between these types of “errors” is that 
sloppiness is not systematic. It results in results that are as often 
positive as negative. If an investigator is simply mischaracterizing 
information, he might record that the patient got better when, in 
fact, the patient got worse. However, it is just as likely to say the 
patient got worse when the patient actually got better. 
Again, this “error” is detected by scientific replication, and it is 
not a commonly encountered problem. What is a much more 
common and serious confounding variable is biologic 
heterogeneity.11 In fact, it is universal. By this I simply mean that 
everyone is different. This is obvious, but it is an under-
appreciated fact. With respect to age and gender, race and co-
morbid conditions people vary greatly. Some people have 
                                                          
24-25 (discussing fabrication of some medical experiments in which the patients 
were unknowingly subjected to certain drugs). 
11 See U.S. Food & Drug Admin., supra note 6. 
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hypertension; some have diabetes; some have asthma. Some 
people have several kinds of diseases simultaneously. How do 
those co-morbid conditions influence an interpretation of the risks 
or benefits of a medicine? Someone may be taking an 
antihistamine and also may have a history of migraine headaches. 
Everyone has different medical conditions and has a different 
constellation of physical attributes and findings. Likewise, not only 
must one consider concurrent prescription medications, one must 
also consider dietary supplements, or vitamins, or other over-the-
counter medications. 
Finally, there is the overwhelming condition of humanness—
our mosaic genetic uniqueness. It is what makes people 
wonderfully varied and also makes it so terribly difficult to 
develop new drugs. Since everybody is biologically different, 
trying to characterize how a product will affect a whole population 
of people is going to necessarily be imperfect and imprecise. 
What are some of the explanations for lack of efficacy or 
severe toxicity? These are questions encountered every day by 
judges on the bench. Someone says, “I didn’t get the benefit that 
was promised.” Or, “I got a toxicity that I didn’t anticipate or I 
wasn’t warned about.” There are a large number of possible 
reasons, but commonly encountered ones include the following: 
First of all, the patient may have had the “wrong” condition. There 
may have been a misdiagnosis. Perhaps the physician thought that 
the patient had diabetes, when actually the patient had a rare form 
of adrenal tumor. Both conditions can result in elevated blood 
sugar but there was a misdiagnosis. The patient was treated with a 
medicine appropriate for diabetes, but the patient actually had a 
different disease. Perhaps the patient actually had diabetes, but the 
doctor mistakenly prescribed a medication that he thought was for 
diabetes. Perhaps this particular medicine really is not effective for 
diabetes patients—he made a mistake. Or there was simple 
confusion—the name of two medicines sound similar, or the 
pharmacy dispensed the wrong drug, or the physician was sleep 
deprived that day, or whatever other excuse. 
Alternatively, the medication prescribed was completely 
appropriate for that condition, but it was prescribed at the wrong 
dose or schedule. Instead of taking it for two weeks, the patient 
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took it for one day. Or the patient took it every other day. Or the 
patient stopped taking the medication before they were supposed 
to. Was that because of physician error? Did the physician write, 
“Take this every day for two weeks and do not stop.” Or, “Take 
this indefinitely?” Or was there patient error? The patient may say, 
“You know, I just do not like to take drugs. I know that doctor 
gave me the medicine, but I am not going to take it.” Or, “I am not 
going to take it three times a day. I will take it once a day. And 
maybe I won’t take it for two weeks. I will take it for two days.” 
There is also recognized heightened sensitivity to toxicity for 
certain patients with certain disease or metabolism variants.12 We 
know that in every drug package insert there is information on how 
many patients are likely to have a toxicity (such as a skin reaction). 
Although there is general information, we are usually unable to 
accurately predict which particular patient will have which serious 
side effect. 
Moreover, we may be able to describe side effects, but there 
may be disagreements about what constitutes a major “side effect.” 
It is like definition of major surgery (popularly attributed to Mel 
Brooks). That is, “minor surgery is anything that happens to 
someone else, but major surgery is any procedure that I have.” 
Moreover, for patients who are critically ill and have few if any 
alternatives, the tolerance for more toxicity is greater.13 
Finally, (sadly) there are a host of unknown factors that 
physicians and scientists poorly understand which determine 
efficacy and toxicity. In this regard, the importance of accurate 
adverse event reporting cannot be exaggerated. Unfortunately, 
however, these events are only infrequently reported. It is even 
difficult to ascertain what fractions are properly captured. It is 
popularly believed that less than 10% of the true adverse events are 
reported. Even when they are reported, they may not be reported 
                                                          
12 See U.S. Food & Drug Admin, supra note 6 (discussing elderly people’s 
heightened sensitivity to due to drug metabolism and interaction problems). 
13 See Vivian I. Orlando, Note and Comment, The FDA’s Accelerated 
Approval Process: Does the Pharmaceutical Industry Have Adequate Incentives 
for Self-Regulation?, 25 AM. J.L. & MED. 543 (describing how terminally-ill 
patients advocated for accelerated approval of new drugs by the FDA, even 
though information about the drug’s safety and effectiveness was preliminary). 
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accurately. 
Adverse Event Reports are toxicities that are unusual, or 
unanticipated, or severe, and come from a variety of sources.14 
They are reported to FDA sometimes by the health care provider. 
The manufacturer is charged with gathering this information and 
regularly sending it to FDA. At FDA these data are tabulated and 
analyzed. With sufficiently clear information there are good 
examples where the agency has taken definitive action. 
CONCLUSION 
Since we all learn a lot more about a drug after more patients 
take it over longer periods of time, FDA must watch carefully and 
be prepared to act. So what then is my estimate of the meaning, the 
value, of FDA review? I deeply respect the agency and the 
scientists and staff who work there. It is like many large 
bureaucracies. There are, of course, some less motivated and less 
talented staff, but generally it is an agency made up of incredibly 
well-intentioned, hard-working, smart, principled individuals. Very 
strong general information is provided for populations of patients 
who are subjects. Information that is reliably valid. I think there is 
useful information provided about individual patients or subjects, 
but that information is imperfect (for the reasons that I have 
outlined above). In some ways it is a problem of epistemology. We 
know what we know about an individual drug because it is 
revealed by progressive revelation more often than through a 
particular epiphany. The FDA review has real integrity and is 
incredibly important, powerful, and useful. But, by itself, it may 
not be determinative for a judge sitting on a case. That said, 
without a doubt, FDA review should help form a substantial part of 
the basis for a decision. 
 
                                                          
14 21 C.F.R. § 314.80 (1999). 
